Why did Quest raise its cash flow guidance so significantly?

Year-to-date operating cash flow rose to $1.42 billion from $870 million, driven by higher net income, non-cash items such as depreciation and amortization and deferred taxes, and favorable working capital changes in accounts payable and accrued expenses. The filing does not break out the precise drivers of the raised full-year guidance to approximately $1.8 billion, so investors should review the earnings call for management's explanation of how much is timing versus sustainable.

What is the difference between reported and adjusted EPS, and why does it matter?

Reported diluted EPS is calculated under GAAP and was $2.16 in Q3. Adjusted EPS of $2.60 excludes items such as restructuring and integration charges, amortization of intangibles, a $15 million legal charge, a $29 million impairment in the year-to-date period, and excess tax benefits from stock compensation. Amortization alone accounted for $0.25 per share in the quarter. Investors should evaluate both measures, since the gap reflects recurring acquisition-related amortization and some recurring-looking restructuring costs.

Is the Corewell Health joint venture material to Quest's financials?

The filing does not disclose the financial terms, ownership split, or revenue contribution of the Corewell joint venture. The company indicates Co-Lab Solutions revenue is expected to reach approximately $1 billion annually next year as services scale across 21 hospitals, which would be a meaningful growth driver if achieved. Investors should look for additional detail in subsequent filings or management commentary on the deal's economics.

Did Quest's full-year revenue guidance change meaningfully?

Yes. Revenue guidance was raised to $10.96–$11.00 billion from $10.80–$10.92 billion, implying 11.0%–11.4% growth versus the prior 9.4%–10.6%. Part of the increase reflects acquisitions completed during the year, including the Fresenius dialysis testing assets, so organic growth should be evaluated separately. Q3 organic growth was 6.8% against 13.1% total growth.

DGX 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed October 21, 2025. Cited figures are marked; the original filing is the authoritative source.

Quest Diagnostics (DGX) reported third quarter 2025 results on October 21, 2025, with revenues of $2.82 billion^a, up 13.1% year over year, including 6.8% organic growth.

Reported diluted EPS was $2.16^b (up 8.5%), and adjusted diluted EPS was $2.60 (up 13.0%). Year-to-date operating cash flow reached $1.4 billion, up 63.1%, driven largely by working capital and tax dynamics that management highlighted alongside improved profitability. Adjusted operating margin expanded 80 basis points to 16.3%, though reported GAAP results include restructuring, legal, and amortization items that investors should weigh alongside the adjusted figures.

Management raised full-year 2025 guidance. Net revenue is now expected at $10.96 to $11.00 billion^c (11.0% to 11.4% growth), up from $10.80 to $10.92 billion. Reported diluted EPS guidance is $8.58 to $8.66 (narrowed and lowered at the low end versus the prior $8.60 to $8.80 range), while adjusted diluted EPS guidance rose to $9.76 to $9.84 from $9.63 to $9.83.

Operating cash flow guidance was lifted substantially to approximately $1.8 billion^d from approximately $1.55 billion. Strategically, the company announced a lab services joint venture with Corewell Health in Michigan, with Co-Lab Solutions expected to reach roughly $1 billion in annual revenue next year across 21 hospitals.

It also completed the acquisition of select dialysis testing assets from Fresenius Medical Care and began scaling testing for its U.S. dialysis centers, and formed consumer channel collaborations with WHOOP and OURA. The filing is a Form 8-K furnishing the earnings press release under Item 2.02, and the disclosed figures are unaudited.

02—Key points

Key Highlights

Q3 2025 net revenues of $2.82 billion, up 13.1% YoY, with 6.8% organic growth and contributions from acquisitions and consumer channel expansion.
Q3 reported diluted EPS of $2.16 (up 8.5%); adjusted diluted EPS of $2.60 (up 13.0%), with adjusted operating margin of 16.3%, up 80 basis points.
Year-to-date operating cash flow of $1.4 billion, up 63.1%; full-year 2025 operating cash flow guidance raised to approximately $1.8 billion from approximately $1.55 billion.
Full-year 2025 revenue guidance raised to $10.96–$11.00 billion (11.0%–11.4% growth) from $10.80–$10.92 billion.
Full-year adjusted diluted EPS guidance raised to $9.76–$9.84 from $9.63–$9.83; reported diluted EPS guidance of $8.58–$8.66 narrowed, with a lower low end than the prior $8.60.
Corewell Health lab services joint venture in Michigan, with Co-Lab Solutions expected to reach about $1 billion in annual revenue next year across 21 hospitals.
Completed acquisition of select dialysis testing assets from Fresenius Medical Care, with an enterprise agreement serving approximately 200,000 dialysis patients annually.

03—Questions

Frequently Asked Questions

Why did Quest raise its cash flow guidance so significantly?
Year-to-date operating cash flow rose to $1.42 billion from $870 million, driven by higher net income, non-cash items such as depreciation and amortization and deferred taxes, and favorable working capital changes in accounts payable and accrued expenses. The filing does not break out the precise drivers of the raised full-year guidance to approximately $1.8 billion, so investors should review the earnings call for management's explanation of how much is timing versus sustainable.
What is the difference between reported and adjusted EPS, and why does it matter?
Reported diluted EPS is calculated under GAAP and was $2.16 in Q3. Adjusted EPS of $2.60 excludes items such as restructuring and integration charges, amortization of intangibles, a $15 million legal charge, a $29 million impairment in the year-to-date period, and excess tax benefits from stock compensation. Amortization alone accounted for $0.25 per share in the quarter. Investors should evaluate both measures, since the gap reflects recurring acquisition-related amortization and some recurring-looking restructuring costs.
Is the Corewell Health joint venture material to Quest's financials?
The filing does not disclose the financial terms, ownership split, or revenue contribution of the Corewell joint venture. The company indicates Co-Lab Solutions revenue is expected to reach approximately $1 billion annually next year as services scale across 21 hospitals, which would be a meaningful growth driver if achieved. Investors should look for additional detail in subsequent filings or management commentary on the deal's economics.
Did Quest's full-year revenue guidance change meaningfully?
Yes. Revenue guidance was raised to $10.96–$11.00 billion from $10.80–$10.92 billion, implying 11.0%–11.4% growth versus the prior 9.4%–10.6%. Part of the increase reflects acquisitions completed during the year, including the Fresenius dialysis testing assets, so organic growth should be evaluated separately. Q3 organic growth was 6.8% against 13.1% total growth.

04—Continue

← View all 8-K filings